Evaluation of the efficacy and safety of a fixed-dose, single-capsule budesonide-formoterol combination in uncontrolled asthma: A randomized, double-blind, multicenter, controlled clinical trial;Avaliação da eficácia e segurança da associação de budesonida e formoterol em dose fixa e cápsula única no tratamento de asma não controlada: Ensaio clínico randomizado, duplo-cego, multicêntrico e controlado

Jornal Brasileiro de Pneumologia

Volumn 38, Issue 4, 2012, Pages 431-437

  Stirbulov, Roberto ^a   Fritscher, Carlos Cezar ^b   Pizzichini, Emilio ^c   Pizzichini, Márcia Margaret Menezes ^c  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Adrenergic beta 2 receptor agonists; Asthma; Budesonide

Indexed keywords

EID: 84866407867     PISSN: 18063713     EISSN: 18063756     Source Type: Journal    
DOI: 10.1590/s1806-37132012000400004     Document Type: Article

References (12)

1. Global Initiative for Asthma - GINA [homepage on the Internet]. Bethesda: Global Initiative for Asthma. [cited 2011 Apr 1]. Global Strategy for Asthma Management and Prevention 2010 [Adobe Acrobat document, 119p.]. Available from: http://www.ginasthma.org/pdf/GINA_Report_2010.pdf
2. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143-178. PMid:18166595. http://dx.doi.org/10.1183/09031936.00138707
3. IV Brazilian Guidelines for the management of asthma [Article in Portuguese]. J Bras Pneumol. 2006;32 Suppl 7:S447-S474. PMid:17420905.
4. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994;344(8917):219-224. http://dx.doi.org/10.1016/S0140-6736(94)92996-3
5. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337(20):1405-1411. PMid:9358137. http://dx.doi.org/10.1056/NEJM199711133372001
6. O'Byrne PM. Therapeutic strategies to reduce asthma exacerbations. J Allergy Clin Immunol. 2011;128(2):257-263; quiz 264-5. PMid:21531015. http://dx.doi.org/10.1016/j.jaci.2011.03.035
7. Sociedade Brasileira de Pneumologia e Tisiologia. I Consenso Brasileiro sobre espirometria. J Pneumol. 1996;22(1):105-164.
8. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B. The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. Am Rev Respir Dis. 1976;113(5):587-600. PMid:1267262.
9. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flowvolume curve with growth and aging. Am Rev Respir Dis. 1983;127(6):725-734. PMid:6859656.
10. Johnson M. Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(3):200-206. PMid:16113435. http://dx.doi.org/10.1513/pats.200402-010MS
11. Giembycz MA, Kaur M, Leigh R, Newton R. A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol. 2008;153(6):1090-10104. PMid:18071293 PMCid:2275445. http://dx.doi.org/10.1038/sj.bjp.0707627
12. van den Berge M, ten Hacken NH, Cohen J, Douma WR, Postma DS. Small airway disease in asthma and COPD: clinical implications. Chest. 2011;139(2):412-423. Erratum in: Chest. 2011;139(4):972. http://dx.doi.org/10.1378/chest.10-1210